Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cross infection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    103 result(s) found for: Cross infection. Displaying page 4 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2008-005855-61 Sponsor Protocol Number: 1100.1518 Start Date*: 2009-05-20
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: An open-label, multiple dose, cross-over study to evaluate the steady-state pharmacokinetic parameters of nevirapine extended release tablets in HIV-1 infected children, with an optional extension ...
    Medical condition: HIV-1 infected children under antiretroviral therapy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000261-36 Sponsor Protocol Number: 1.0 Start Date*: 2021-01-27
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRINCULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED F...
    Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient's qu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005758-36 Sponsor Protocol Number: UTX-TGR-304 Start Date*: 2016-10-28
    Sponsor Name:TG Therapeutics
    Full Title: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chr...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001310-38 Sponsor Protocol Number: CAPSID2020-DRK-BSD Start Date*: 2020-04-06
    Sponsor Name:DRK-Bluspendedienst Baden-Württemberg - Hessen gGmbH
    Full Title: A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19
    Medical condition: Patients with SARS-CoV-2 infection and: 1. age ≥ 18 years and ≤ 75 years 2. SARS-CoV-2 infection confirmed by PCR (BAL, sputum, nasal and/or pharyngeal swap) 3. severe disease ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10047475 Viral pneumonia, unspecified LLT
    23.0 100000004848 10070267 SARS virus test positive LLT
    20.0 100000004865 10021433 Immunization LLT
    21.1 100000004865 10054540 Passive immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2020-002542-16 Sponsor Protocol Number: INSIGHT013 Start Date*: 2020-09-30
    Sponsor Name:Office of Sponsored Projects, Regents of the University of Minnesota
    Full Title: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the...
    Medical condition: COVID-19 (SARS-CoV-2) infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000844-13 Sponsor Protocol Number: SMR-2984 Start Date*: 2014-09-25
    Sponsor Name:Algipharma AS
    Full Title: A double-blind, randomized, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis.
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023235-41 Sponsor Protocol Number: 12012.101 Start Date*: Information not available in EudraCT
    Sponsor Name:PARI Pharma GmbH
    Full Title: A comparative, randomised, two period, multi-center, cross-over 14 weeks bioequivalence study of Tobramycin PARI (T100) versus TOBI® (Novartis) in cystic fibrosis patients with bronchopulmonary chr...
    Medical condition: Cystic fibrosis with bronchopulmonary chronic Pseudomonas aeruginosa infection
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011763 Cystic fibrosis lung LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000436-62 Sponsor Protocol Number: GS-US-380-4547 Start Date*: 2021-02-12
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability and Food Effect of a Pediatric Tablet for Oral Suspension of Bictegravir/Emtricitabine/Tenofovir Alafenamide and the...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004786-80 Sponsor Protocol Number: ANAKIN Start Date*: 2019-02-20
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty
    Full Title: A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis.
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10028141 Mucoviscidosis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000946-69 Sponsor Protocol Number: AZ07 Start Date*: 2016-07-05
    Sponsor Name:AZAD Pharma AG
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, INVESTIGATOR-MASKED, CROSS- OVER, COMPARATIVE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF THE GENERIC BRINZOLAMIDE 10 MG/ML + TIMOLOL 5 MG/ML EYE DROP...
    Medical condition: Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction
    Disease: Version SOC Term Classification Code Term Level
    19.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    19.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005159-18 Sponsor Protocol Number: CRO2047 Start Date*: 2013-08-28
    Sponsor Name:Imperial College, London
    Full Title: An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS)
    Medical condition: Septic shock.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004867 10028237 Multiple organ failure LLT
    16.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004008-36 Sponsor Protocol Number: VRV09 Start Date*: 2020-09-07
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Purified Vero Rabies Vaccine– Serum Free (VRVg) Assessed with the Institut Pasteur du Cambodge (IPC: 2-2-2-0-0) and the Thai Red Cross (TRC: 2-2-2-0-2) Intradermal Re...
    Medical condition: Rabies (Healthy Volunteers)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037742 Rabies PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-003675-36 Sponsor Protocol Number: COLO/DPI/02/06 Start Date*: 2005-04-28
    Sponsor Name:Forest Laboratories UK Ltd
    Full Title: A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOB...
    Medical condition: Pseudomonas aeruginosa (PA) infection in patients with cystic fibrosis.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) AT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004420-35 Sponsor Protocol Number: GS-US-104-0423 Start Date*: 2013-02-13
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects
    Medical condition: Human Immunodeficiency Virus-1 (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) AT (Completed) NL (Completed) IT (Completed) IE (Completed) PT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004314-29 Sponsor Protocol Number: CCD-06235AA1-01 Start Date*: 2015-02-27
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: MULTICENTRE, OPEN LABEL, RANDOMIZED, TWO-ARM, PARALLEL-GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF ENVARSUS® COMPARED WITH TACROLIMUS USED AS PER CURRENT CLINICAL PRACTICE IN THE INITIAL MAINTENAN...
    Medical condition: ESRD (end stage renal disease)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) ES (Completed) DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004429-15 Sponsor Protocol Number: GEM-1402 Start Date*: 2016-02-16
    Sponsor Name:GRUPO ESPAÑOL MULTICISPLINAR DE MELANOMA
    Full Title: Phase II multicente, non randomized, open label trial of nivolumab in combination with ipilimumab in subjects with previously untreated metastatic uveal melanoma.
    Medical condition: Metastatic uveal melanoma non suitable for radical resection.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002412-10 Sponsor Protocol Number: D5892C00012 Start Date*: 2007-04-25
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, double-dummy, two-way cross-over study evaluating systemic bioavailability and airway clearance of Symbicort® Turbuhaler® 320/9μg/inhalation versus Seretide™ Diskus ™...
    Medical condition: This is a Clinical Pharmacology study to be conducted in one patient group with severe COPD and one group of healthy volunteers.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000841-12 Sponsor Protocol Number: 215.1364 Start Date*: Information not available in EudraCT
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised open label, six way, cross-over scintigraphic evaluation of the effect of inspiratory flow rate on lung and oropharyngeal deposition with the Respimat(R) inhaler vs a Metered Dose Inha...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) is characterised by airflow limitation and bronchial inflammation. Clinically, COPD is characterised by progressive dyspnoea on exertion and intermitten...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10010952 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001104-23 Sponsor Protocol Number: CSLCT-BIO-07-47 Start Date*: 2009-01-22
    Sponsor Name:CSL Behring GmbH
    Full Title: A Phase II, multicentre, double-blinded, randomised, cross-over study to evaluate efficacy, safety and pharmacokinetics of Biostate® in subjects with Haemophilia A.
    Medical condition: Haemophilia A - a hereditary bleeding disorder characterised by a deficiency in the plasma protein known as coagulation Factor VIII (FVIII).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-014807-30 Sponsor Protocol Number: Fluval P-H-07 Start Date*: 2009-08-13
    Sponsor Name:Omninvest Ltd.
    Full Title: Tolerability and Immunogenicity Study of Fluval P Monovalent Influenza Vaccine in Children and Adolescents
    Medical condition: Immunization of children and adolescents against infection caused by pandemic influenza (H1N1)09 virus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059429 Influenza immunisation LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 14:15:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA